No Data
No Data
Is Now The Time To Put Guizhou Sanli PharmaceuticalLtd (SHSE:603439) On Your Watchlist?
guizhou sanli pharmaceutical co.,ltd. (603439.SH): has repurchased 1.92% of shares accumulated.
On October 8, Guizhou Sanli Pharmaceutical Co.,Ltd. (603439.SH) announced that as of September 30, 2024, the company has repurchased a total of 7,869,300 shares through centralized competitive trading, accounting for 1.92% of the total share capital of the company as of the date of this announcement. The highest repurchase price was RMB 14.20 per share, the lowest repurchase price was RMB 11.82 per share, and the total amount paid was RMB 99,954,426.00 (excluding transaction fees).
guizhou sanli pharmaceutical co.,ltd. (603439.SH): Proposes to launch a restricted stocks incentive plan for 5.23 million shares.
gelonhui October 8th, guizhou sanli pharmaceutical co.,ltd. (603439.SH) announced the 2024 restricted stock incentive plan, which grants 5.23 million restricted stocks, accounting for 1.2762% of the total number of company stocks of 409.802216 million shares on the announcement date of the incentive plan draft.
guizhou sanli pharmaceutical co.,ltd. (603439.SH): Guoshenghaitong private enterprise high-quality development fund's shareholding has decreased to below 5%.
On September 25, Gelonhui reported that Guizhou Sanli Pharmaceutical Co., Ltd. (603439.SH) disclosed that on September 24, 2024, Guoshenghaitong private enterprise high-quality development fund reduced its holdings of the company's unrestricted circulating shares by 9,900 shares through centralized competitive bidding on the Shanghai Stock Exchange. The reduction accounted for 0.002416% of the company's total share capital. After this equity change, Guoshenghaitong private enterprise high-quality development fund holds 20,490,100 shares of the company, accounting for 4.999997% of the total share capital, no longer a shareholder holding more than 5% of the company.
guizhou sanli pharmaceutical co.,ltd. (603439.SH) intends to acquire 40% equity of its subsidiary sankang partnership.
Guizhou Sanli (603439.SH) announced that the company intends to acquire Guizhou Healthy Agricultural Traditional Chinese Medicine Industry Development Group...
Guizhou Sanli Pharmaceutical Co.,Ltd. (603439.SH): Subsidiary plans to increase capital with related parties in Chengdu Dimension Era.
On September 20, Guizhou Sanli (603439.SH) announced that in order to promote the company's business development, its wholly-owned subsidiary Sanli Health intends to increase capital in Chengdu Dimensional Times jointly with Chuangjian Yongsheng, Yaozunbao, and Changan Technology, with a total capital increase of 70 million yuan. This transaction is based on the registered capital as the price basis. After the completion of this transaction, the registered capital of Chengdu Dimensional Times will increase from 10 million yuan to 80 million yuan, of which Sanli Health, a wholly-owned subsidiary of the company, will contribute 20 million yuan and hold a 25.00% stake, while Chuangjian Yongsheng will contribute 34.8 million yuan and hold a...
No Data
No Data